瑞銀料SPAC會加倍留意亞洲標的公司
瑞銀預計,今年至明年,特殊目的收購公司(SPAC)會加倍留意亞洲的併購標的公司,料大部分SPAC重點併購電商、教育、科技等高增長行業,雖然美國證券交易委員會(SEC)最近加強審查在美國掛牌交易的中國企業,不過這個趨勢並無令SPAC停止與中國的標的公司商討併購。
瑞銀全球投資銀行部亞洲併購部主管盧穗誠在電話會議中表示,目前未有首間新加坡或香港的SPAC上市,仍需要一段時間觀察日後新加坡會否成爲亞洲SPAC併購重心。他又說,在內地上市涉及較長的禁售期,而投資SPAC的多爲短線投資者,認爲可以觀察內地日後有沒有允許SPAC上市的新方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.